CalciMedica, Inc.

Develops CRAC channel inhibitors for critical illnesses like acute pancreatitis & AKI.

CALC | NDAQ

Overview

Corporate Details

ISIN(s):: US38942Q2021 (+1 more)
LEI:
Country:: United States of America
Address:: 505 COAST BOULEVARD SOUTH, 92037 LA JOLLA
Website:: https://calcimedica.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for life-threatening acute inflammatory and immunologic diseases. The company specializes in a new class of treatments based on the inhibition of calcium release-activated calcium (CRAC) channels, which are designed to modulate the immune response and protect against tissue cell injury. Its lead product candidate, Auxora™ (zegocractin), is a proprietary small molecule CRAC channel inhibitor being developed for critical care illnesses with high unmet needs, including acute kidney injury (AKI) and acute pancreatitis (AP), for which there are currently no approved disease-modifying treatments.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all CalciMedica, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CalciMedica, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for CalciMedica, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Human Stem Cells Institute PJSC A biotech investor developing gene therapy, regenerative medicine, and genetic services.	Russian Federation	ISKJ
HUMASIS CO., LTD. Develops & manufactures rapid in-vitro diagnostic test kits & instruments for global POCT markets.	South Korea	205470
Humedix Co., Ltd. Develops hyaluronic acid-based pharma, aesthetics, medical devices, and offers CMO services.	South Korea	200670
HUONS CO., LTD. Global healthcare company providing pharmaceuticals, medical devices, and wellness products.	South Korea	243070
Huons Global Co., Ltd. Develops pharmaceuticals, medical devices, cosmetics, and health foods for the global market.	South Korea	084110
Hutchmed (China) Limited	Hong Kong	HCM
HUTCHMED (China) Ltd Develops and commercializes targeted therapies for cancer and immunological diseases worldwide.	United States of America	HCM
HWAIL PHARM. CO., LTD Develops and manufactures APIs, finished drugs, and functional ingredients for healthcare.	South Korea	061250
Hyloris Pharmaceuticals SA A biopharma company optimizing existing drugs for unmet needs via abbreviated pathways.	Belgium	HYL
HYUNDAI BIOLAND Co.,Ltd. Develops natural biomaterials for cosmetics, nutraceuticals, and regenerative medicine globally.	South Korea	052260